CSL Limited Annual Report 2022/23 4 1 Chair and CEO Message CEO Message Dear Shareholders, I am honoured to be writing to you as Chief Executive Officer and Managing Director of CSL, a role in which I began in March 2023. Since joining CSL as Chief Operating Officer, I have been accountable for optimising CSL’s operations as well as growing the CSL Seqirus, CSL Behring and CSL Vifor businesses. Along with the current management team, I have been intimately involved in developing CSL’s 2030 Strategy – from development to execution. My predecessor Paul Perreault was an exceptional leader and oversaw a decade of great success for CSL. I have inherited a highly motivated, valuesbased teamwith a relentless focus on continuing our purpose-driven journey of sustainable and profitable growth. Building on Success At CSL, given the essential nature of our work, the iconic history of our company, and the world-class quality of our team, I am truly humbled and, at the same time, extremely excited to be your CEO. For more than a century, we have been driven by our promise to patients. This has distinguished CSL, defining our strong position as one of the world’s leading biotech companies. Our purpose, values, and promise remain steadfast and even more relevant in today’s complex, and evolving world. The formula that has enabled CSL to deliver value for a variety of stakeholders throughout our history is proven. On page 23 you can read about 2030 Strategy. CSL will continue to follow this strategy under my leadership, but as I look forward over the medium term, I see the following five priorities: 1. Leverage our scale and execute on our commercial portfolios and innovation agendas. 2.Evolve and differentiate our vaccine platform. 3.Unlock the value and growth within CSL Vifor. 4.Drive further improvement in CSL Behring margins. 5.Be an employer of choice and a strategic partner of choice. Playing to Our Strengths I believe CSL is uniquely equipped to contribute in the next era of innovation and tomake a lasting impact on communities around the world. CSL’s many strengths position us well for the future, as shown in the following examples. • We deliver innovative life-saving medicines in over 100 countries. • Every day, more than 342 plasma collection centres enhance donor experiences and provide our critical rawmaterial to save lives. • Our R&D pipeline has never been more robust or more promising. • Productivity and efficiency remain hallmarks and competitive advantages for CSL. Our network strategy is robust, and we are bringing on new capacity and capabilities around the globe.
RkJQdWJsaXNoZXIy MjE2NDg3